**Second Hypertension CME symposium: Advances in Blood Pressure Measurement and Management**

June 7, 2025

**Error! Unknown op code for conditional.**

**Target Audience**

Specialties – Anesthesiology & Perioperative Care, Dermatology, Emergency Medicine, Family Medicine, Medicine, Neurological Surgery, Neurology, Obstetrics & Gynecology, Ophthalmology, Orthopaedic Surgery, Otolaryngology - Head & Neck Surgery, Pathology & Laboratory Medicine, Pediatrics, Physical Medicine & Rehabilitation, Plastic Surgery, Psychiatry & Human Behavior, Radiation Oncology, Radiological Sciences, Surgery, Urology, Other

Professions – Physician, Non-Physician, Allied Health Professional, Dentist, Medical Assistant, Medical Student, Nurse, Nurse Practitioner, Other, Paramedic, Pharmacist, Physician Assistant, Registered Dietitian, Resident Physician, Speech-Language Pathologist, Psychologist

**Activity Objectives**

1 provide education related to blood pressure measurements and management for healthcare providers who measure blood pressure or manage abnormal blood pressure.

2 train accurate blood pressure measurement for healthcare providers who measure blood pressure

3 implement blood pressure measurement and hypertension management in consistent with patients from different backgrounds in terms of cultural and linguistic competency.

**Accreditation Statement**

The University of California, Irvine School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

**Designation Statement**

The University of California, Irvine School of Medicine designates this Live Activity for a maximum of 5.75 *AMA PRA Category 1 Credit(s)*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**California Assembly Bill 1195 and 241**

This activity is in compliance with California Assembly Bill 1195 and 241, which require CME activities with patient care components to include curriculum in the subjects of cultural and linguistic competency & implicit bias. It is the intent of AB 1195 and AB 241 to encourage physicians and surgeons, CME providers in the State of California, and the Accreditation Council for Continuing Medical Education to meet the cultural and linguistic concerns of a diverse patient population and reduce health disparities through appropriate professional development. Please see the CME website, <https://www.meded.uci.edu/CME/> for AB 1195 and AB 241 resources.



A close-up of a sign

AI-generated content may be incorrect.

ABIM
CME
MOC
Accredited

ABIM
CME
MOC
Accredited

CME for
ABPath CC

Part 2
MOC
The American Board of Pediatrics

**MOC Statement(s)**

ABIM
CME
MOC
AccreditedSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 5.75 MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Through the American Board of Medical Specialties (“ABMS”) ongoing commitment to increase access to practice relevant Continuing Certification Activities through the ABMS Continuing Certification Directory, the **2nd Hypertension Symposium: Blood Pressure Measurements and Managements** has met the requirements as a Lifelong Learning CME Activity for the following ABMS Member Boards:

**Family Medicine**

**Faculty & Planner Disclosures**

University of California, Irvine School of Medicine Continuing Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

|  |  |  |
| --- | --- | --- |
| **Name of individual** | **Individual's role in activity** | **Nature of Relationship(s) / Name of Ineligible Company(s)** |
| Steven Vasquez | Activity Coordinator | Nothing to disclose - 10/28/2024 |
| Stefaney Mendoza, BA | Activity Coordinator | Nothing to disclose - 03/05/2025 |
| Nathan D. Wong, PhD, MPH | Faculty, Planning Commitee Member | Grant or research support-Novartis Corporation Pharmaceuticals|Consulting Fee-Novartis Corporation Pharmaceuticals|Consulting Fee-Amgen, Inc.|Consulting Fee-Ionis Pharmaceuticals|Grant or research support-Novo Nordisk (Any division) (Relationship has ended)|Consulting Fee-Heart Lung|Grant or research support-Amgen, Inc.|Speakers Bureau-Novartis Corporation Pharmaceuticals - 01/06/2025 |
| Nii-Kabu Kabutey, MD | Faculty | Nothing to disclose - 05/05/2025 |
| Alpesh Amin, MD | Faculty | Consulting Fee-Pfizer (Any division)|Consulting Fee-Salix Pharmaceuticals, Inc.|Consulting Fee-Alexion Pharmaceuticals|Consulting Fee-AstraZeneca (Any division)|Consulting Fee-Bayer (Any division)|Consulting Fee-Ferring|Consulting Fee-Seres|Consulting Fee-Spero|Consulting Fee-Eli Lilly|Consulting Fee-Novo Nordisk (Any division)|Consulting Fee-Gilead Sciences, Inc.|Consulting Fee-Renibus|Consulting Fee-GSK|Consulting Fee-Dexcom|Consulting Fee-Reprieve|Consulting Fee-HeartRite|Consulting Fee-Aseptiscope - 11/30/2024 |
| Alisa Wray, MD, Physician | Faculty | Nothing to disclose - 04/14/2025 |
| Pengbo Jiang, MD | Faculty | Nothing to disclose - 05/06/2025 |
| Rebecca Bennett, MD | Faculty | Nothing to disclose - 05/02/2025 |
| Madeleine V Pahl, MD | Faculty | Grant or research support-Sangamo Therapeutics - 06/24/2024 |
| Pranav Patel, MD | Faculty | Nothing to disclose - 03/26/2025 |
| Wei Ling Lau, MD | Faculty, Planning Commitee Member | Nothing to disclose - 04/09/2025 |
| Ekamol Tantisattamo, MD, MPH, FACP, FASN, FNKF, FAST, FAHA, FASDIN, FISH, ISHF | Course Director, Faculty | Nothing to disclose - 05/19/2025 |
| Yongen Chang, MD, PhD | Faculty | Other: Received compensation for conducting a webinar. -Otsuka America Pharmaceutical, Inc. (Relationship has ended) - 06/11/2024 |
| Shaista Malik, MD, PhD, MPH, FACC | Faculty | Ownership-FluxWear - 04/29/2025 |
| Lisa Gibbs, MD, Interim Department Chair | Faculty | Nothing to disclose - 12/13/2024 |
| Richard A Lee, MD | Faculty | Nothing to disclose - 05/01/2025 |
| Andrew Odegaard, PhD | Faculty | Nothing to disclose - 05/05/2025 |
| Natalia Ullrich, Master, Clinical Nutrition | Planning Commitee Member | Nothing to disclose - 04/17/2025 |
| Surasak Kantachuvesiri, MD, PhD | Faculty | Nothing to disclose - 04/21/2025 |
| Wenjun Fan, PhD | Faculty | Nothing to disclose - 05/07/2025 |

**Agenda**

**[INSERT AGENDA HERE MANUALLY]**

**Acknowledgement of Commercial Support**

The University of California, Irvine School of Medicine would like to thank Natera and AstraZenica for their financial support of this activity.